Skip to content

A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China

A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03710083
Enrollment
72
Registered
2018-10-17
Start date
2019-02-28
Completion date
2019-07-25
Last updated
2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes Type I Type II

Brief summary

The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.

Detailed description

This study is a multi-center, prospective single-arm design without controls. Up to 72 subjects will be enrolled in order to have approximately 60 subjects complete the study. Three investigational centers in China will be used during this study. During the study, each subject will be randomly assigned to one day of the Yellow Springs Instrument (YSI™\*) frequent sample testing (FST) (Day 1, 3-5, or 7).Subjects will wear two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days (one which will be paired to the Guardian Connect app and the other will function as a glucose recorder.). The Guardian Sensor (3)s will be worn in the abdomen area and self-inserted by the subject on same side or opposite sides. On the evening prior to FST, subjects will be asked to fast for approximately 12 hours and adjust their insulin and medications according to routine care (for example as they would do for fasting lipid panel). Subjects may fast for shorter period of time based on investigator discretion. The subject should be in fasting status upon arrival hospital to start FST process. The feeding protocol may be modified based on investigator discretion. The duration of FST will be approximately 7 hours. During the study, subjects will continue with their current diabetes regimen independent of the study devices. Subjects will be instructed by the investigational center that they are not to use the study devices (except for the CONTOUR™\* study meter) for the management of their diabetes. The CONTOUR™\* study meter may be used for treatment decisions and calibration of Guardian™ Sensor (3).

Interventions

DEVICEGuardian™ Sensor (3)

Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.

Sponsors

Medtronic Diabetes
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is 14 - 75 years of age at time of screening 2. Subject has a clinical diagnosis of type 1 or 2 diabetes as determined via medical record or source documentation by an individual qualified to make a medical diagnosis 3. Subject has adequate venous access as assessed by investigator or appropriate staff 4. Subject is willing to follow the study procedures and willing to come to study visits

Exclusion criteria

1. Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by qualified individual. 2. Subject has any unresolved adverse skin condition in the area of study device or device placement (e.g., psoriasis, rash, Staphylococcus infection) 3. Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks 4. Subject is female and has a positive pregnancy screening test 5. Females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator 6. Subject is female and plans to become pregnant during the course of the study 7. Subject has a hematocrit (Hct) lower than the normal reference range 8. Subject may not be on the research staff of those performing this study

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI168 HoursPercentage of Guardian™ Sensor (3) Values that are within 20% agreement of Yellow Springs Instrument (YSI) plasma glucose values (±20 mg/dL (1.1 mmol/L) when reference blood glucose (YSI) less than or equal to (≤) 80 mg/dL (4.4 mmol/L) ) during YSI frequent sampling testing (FST) days.
Consensus Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B168 HoursA mean rate in Zone A+B of Consensus Error Grid between Guardian Sensor (3) values and YSI™\* plasma glucose values during YSI™\* FST days was evaluated. Consensus Error Grid (or Parkes error grid) compared the paired primary sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of clinical accurate measurements with no effect on clinical action, Zone B as altered clinical action with little or no effect on clinical outcome. Ideal situation is 100% in Zone A + B.
Clarke Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B168 HoursA mean rate in Zone A+B of Clarke Error Grid between Guardian Sensor (3) values and YSI™\* plasma glucose values during YSI™\* FST days was evaluated. Clarke Error Grid compared the paired primary sensor and YSI reference glucose values. Zone A are clinically accurate in that they would lead to clinically correct treatment decisions. Zone B would lead to benign or no treatment. Ideal situation is 100% in Zone A + B.
Mean Absolute Relative Difference (MARD)168 HoursMean absolute relative difference (MARD) between Guardian Sensor (3) values and YSI™\* plasma glucose values during YSI™\* FST days was evaluated. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple FST days were pooled together for reporting purpose.

Countries

China

Participant flow

Pre-assignment details

72 subjects consented and enrolled in the overall study. Of the 72, 3 subjects failed screening, 3 subjects didn't utilize any Guardian™ Sensor (3) , 66 subjects utilized Guardian™ Sensor (3) and were considered to have started in the study.

Participants by arm

ArmCount
Study Arm
Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7). Guardian™ Sensor (3): Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
66
Total66

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyUnsuccessful Procedure1
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicStudy Arm
Age, Continuous45.67 years
STANDARD_DEVIATION 17.1
BMI23.51 kg/m^2
STANDARD_DEVIATION 3.61
Race/Ethnicity, Customized
Han Chinese
64 Participants
Race/Ethnicity, Customized
Hui Chinese
1 Participants
Race/Ethnicity, Customized
Man Chinese
1 Participants
Sex: Female, Male
Female
35 Participants
Sex: Female, Male
Male
31 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 66
other
Total, other adverse events
0 / 66
serious
Total, serious adverse events
0 / 66

Outcome results

Primary

Clarke Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B

A mean rate in Zone A+B of Clarke Error Grid between Guardian Sensor (3) values and YSI™\* plasma glucose values during YSI™\* FST days was evaluated. Clarke Error Grid compared the paired primary sensor and YSI reference glucose values. Zone A are clinically accurate in that they would lead to clinically correct treatment decisions. Zone B would lead to benign or no treatment. Ideal situation is 100% in Zone A + B.

Time frame: 168 Hours

Population: A total of 63 subjects who had Guardian™ Sensor (3) inserted and had at least one paired Guardian™ Sensor (3) value and YSI measurement.

ArmMeasureValue (MEAN)
Study ArmClarke Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B99.8 percentage of paired readings
Primary

Consensus Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B

A mean rate in Zone A+B of Consensus Error Grid between Guardian Sensor (3) values and YSI™\* plasma glucose values during YSI™\* FST days was evaluated. Consensus Error Grid (or Parkes error grid) compared the paired primary sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of clinical accurate measurements with no effect on clinical action, Zone B as altered clinical action with little or no effect on clinical outcome. Ideal situation is 100% in Zone A + B.

Time frame: 168 Hours

Population: A total of 63 subjects who had Guardian™ Sensor (3) inserted and had at least one paired Guardian™ Sensor (3) value and YSI measurement.

ArmMeasureValue (MEAN)
Study ArmConsensus Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B100 percentage of paired readings
Primary

Mean Absolute Relative Difference (MARD)

Mean absolute relative difference (MARD) between Guardian Sensor (3) values and YSI™\* plasma glucose values during YSI™\* FST days was evaluated. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple FST days were pooled together for reporting purpose.

Time frame: 168 Hours

Population: A total of 63 subjects who had Guardian™ Sensor (3) inserted and had at least one paired Guardian™ Sensor (3) value and YSI measurement.

ArmMeasureValue (MEAN)Dispersion
Study ArmMean Absolute Relative Difference (MARD)8.11 percentage of differenceStandard Deviation 4.02
Primary

Percentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI

Percentage of Guardian™ Sensor (3) Values that are within 20% agreement of Yellow Springs Instrument (YSI) plasma glucose values (±20 mg/dL (1.1 mmol/L) when reference blood glucose (YSI) less than or equal to (≤) 80 mg/dL (4.4 mmol/L) ) during YSI frequent sampling testing (FST) days.

Time frame: 168 Hours

Population: A total of 63 subjects who had Guardian™ Sensor (3) inserted and had at least one paired Guardian™ Sensor (3) value and YSI measurement.

ArmMeasureValue (MEAN)
Study ArmPercentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI93.2 percentage of paired readings

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026